Actively Recruiting
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Led by Columbia University · Updated on 2025-10-31
240
Participants Needed
4
Research Sites
219 weeks
Total Duration
On this page
Sponsors
C
Columbia University
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Effective, clinically meaningful treatments are lacking for patients with mild cognitive impairment (MCI), which is associated with increased risk of transition to dementia. Cognitive training represents an important therapeutic strategy. In a previous study, crossword puzzles were found to be superior to computerized cognitive training on the primary cognitive outcome and function with decreased brain atrophy. Building on these findings, this study will evaluate and compare the impact of high dose crosswords (4 puzzles per week) to low dose crosswords (1 puzzle per week) and a health education control group on the cognition and function of participants.
CONDITIONS
Official Title
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Access to a home desktop or laptop computer or tablet with acceptable internet speed for the study duration
- Age between 55 and 89 years at the time of consent
- Females must be post-menopausal (last period over 12 months ago)
- Subjective cognitive complaints such as memory or language issues
- Meet criteria for early or late mild cognitive impairment based on memory testing adjusted for education
- Montreal Cognitive Assessment (MoCA) score of 20 or higher out of 30
- Have an informant who contacts the participant at least weekly to provide information
- Must be English-speaking with at least a 6th grade reading level as measured by WRAT3 score of 37 or higher
You will not qualify if you...
- Diagnosis of any type of dementia
- Current diagnosis of schizophrenia, schizoaffective disorder, psychosis, or bipolar I disorder
- Untreated major depression or active suicidality as determined by screening
- Alcohol or substance use disorder within the past 6 months
- Clinical stroke with lasting neurological deficits
- Use of medications negatively affecting cognition, including certain benzodiazepines, narcotics, and anticholinergics
- Presence of central nervous system infections, Huntington's disease, multiple sclerosis, Parkinson's disease, or other significant neurological disorders
- Severe unstable medical illness or active cancer with metastases
- Contraindications to MRI such as incompatible pacemakers or metal implants
- Regular crossword or computerized cognitive training use once or more per week in the past year
- Participation in another cognitive enhancing clinical trial
- Geriatric Depression Scale score of 6 or higher (short form)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
University of Miami Miller School of Medicine
Miami, Florida, United States, 33136
Actively Recruiting
2
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
3
Duke University Medical Center
Durham, North Carolina, United States, 27710
Actively Recruiting
4
University of Washington
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
L
Lola Nedic, BA
CONTACT
D
Davangere P Devanand, MD, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here